Merve Korkmaz Yilmaz

Merve Korkmaz Yilmaz

Auto-generated profile, based on publicly available information

Merve Korkmaz Yilmaz


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2018 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
STSinan Trabulus
Sinan Trabulus
MKMerve Korkmaz
Merve Korkmaz
EKEda Kaya
Eda Kaya
NSNurhan Seyahi
Nurhan Seyahi

15 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MYMerve Korkmaz Yilmaz
Merve Korkmaz Yilmaz
OAOzlem Kandemir Alibakan
Ozlem Kandemir Alibakan
AGAydeniz Aydin Gumus
Aydeniz Aydin Gumus
AGAlper Gezdirici
Alper Gezdirici
HKHüseyin Karatay
Hüseyin Karatay
EHEsra HATIPOGLU
Esra HATIPOGLU
Background/Objectives: Advances in the genetic understanding of pheochromocytoma–paraganglioma (PPGL) have considerably refined personalized approaches to diagnosis and management. This study aims to present our institutional experience on the diagnostic characteristics, clinical course, and genetic background of patients with PPGL, in the context of the current literature. Methods: This retrospective analysis included 35 patients diagnosed with PPGL between years 2020 and 2024, all of whom underwent surgical resection and next-generation sequencing for germline mutations in major PPGL susceptibility genes. Clinical presentation, biochemical profile, pathological findings, and follow-up outcomes were compared between mutation-positive and mutation-negative cases. Results: Of the 35 patients with PPGL, germline mutations were identified in 6 patients (17%): 2 in Cluster 1A genes (SDHA, SDHB), 2 in Cluster 1B (VHL), and 2 in Cluster 2 (NF1). Consistent with existing literature, pathogenic germline variants—particularly SDHB and VHL—were identified in our cohort exclusively in patients younger than 30 years (ages 17, 20, and 25). Mutation-positive patients more frequently exhibited noradrenergic or non-secretory profiles (p = 0.01). Among the three non-secretory tumors in the cohort, two harbored genetic mutations (SDHA, NF1). Interestingly, both NF1-positive patients were normotensive—one (c.3496G > A) with a non-secretory tumor and the other (c.2329T > A) presenting at an unusually late age (63 years)—a strikingly atypical spectrum that underscores the phenotypic variability of NF1-associated PPGL. Bilateral disease was observed exclusively in VHL carriers (p = 0.03). Importantly, we identified a rare VHL c.369delG frameshift variant, not previously reported in association with PPGLs, in a patient with PPGL. No significant difference was observed between SDHB loss (p = 0.1) and proliferative indices (mitotic count, Ki-67) (p = 0.07, p = 0.6) between the two groups. During a median follow-up of 24 months (IQR: 18–36), one SDHB-positive patient had a recurrence, while no distant metastases were detected in the remaining mutation carriers. Conclusions: These findings support characteristic clinical patterns among mutation-positive PPGL and underscore the importance of systematic germline testing in all cases—irrespective of age, family history, or biochemical profile—to guide individualized management and enable cascade screening. The identification of a rare VHL c.369delG variant, previously unreported in association with PPGL, within a characteristic VHL-related clinical phenotype highlights the importance of this association. Similarly, atypical NF1 cases emphasize phenotypic variability and reinforce the importance of germline testing even in clinically silent presentations.

1 January 2026 in Endocrine Journal
Verified
Journal Article
Closed access
AOAysel Unver Ozkahraman
Aysel Unver Ozkahraman
MYMerve Korkmaz Yilmaz
Merve Korkmaz Yilmaz
HKHüseyin Karatay
Hüseyin Karatay
SBSidar Bagbudar
Sidar Bagbudar
EAEbubekir AKPINAR
Ebubekir AKPINAR
EHEsra HATIPOGLU
Esra HATIPOGLU
Amyloid spherule-containing prolactinomas are rare entities associated with dopamine agonist (DA) resistance and aggressive behaviour. We report a giant amyloid spherule-containing prolactinoma with a substantial tumour burden and markedly elevated prolactin levels, highlighting novel multimodal therapeutic strategies. A 49-year-old man presented with headache and visual disturbance. Imaging revealed a giant pituitary macroadenoma (63 × 84 × 46 mm) with Knosp grade 4 cavernous sinus invasion and clivus erosion. Laboratory investigations revealed marked hyperprolactinemia (prolactin (PRL): 30,969 ng/mL) and autonomous growth hormone (GH) hypersecretion. Histopathology confirmed a sparsely granulated lactotroph tumour with extensive amyloid spherules and dystrophic calcifications (Ki-67: 8%). Notably, immunohistochemistry demonstrated PRL positivity without GH immunoreactivity, suggesting tumour heterogeneity with sampling limitations. Comprehensive systemic amyloidosis screening, the first systematic evaluation reported for this entity, excluded systemic disease. Following surgical debulking with extensive residual disease, postoperative cabergoline treatment resulted in a reduction in the PRL (4,700→927 ng/mL). Given the presence of amyloid-associated dopamine resistance, cabergoline was discontinued, and radiotherapy (RT) (45 Gy) was initiated to control the amyloid burden, followed by temozolomide. Based on evidence from other malignancies suggesting RT-mediated amyloid reduction, cabergoline was reintroduced postradiotherapy without paradoxical tumour growth. Concurrent cabergoline-temozolomide therapy, a novel approach that differs from conventional sequential protocols, achieved a dramatic response: 93.4% prolactin reduction (10,320→677 ng/mL) and 52.4% tumour volume reduction. This superior outcome far exceeded that of initial postsurgical cabergoline monotherapy (80% reduction), suggesting that RT successfully modulated the amyloid burden and restored dopamine sensitivity. This case suggests that RT may restore dopamine agonist sensitivity in patients with amyloid-containing prolactinomas, potentially enabling concurrent dopamine agonist-temozolomide therapy in refractory cases, warranting further validation.

1 January 2026 in Eurasian Journal of Medical Investigation
Verified
Journal Article
Closed access
PDF file
MYMerve Korkmaz Yilmaz
Merve Korkmaz Yilmaz
EHEsra HATIPOGLU
Esra HATIPOGLU
Ejmi Eurasian Journal of Medical Investigation

3 January 2019 in Turkish Journal of Nephrology
Verified
Journal Article
Closed access
MKMerve Korkmaz
Merve Korkmaz
EKEda Kaya
Eda Kaya
AKAlican Karakoç
Alican Karakoç
STSinan Trabulus
Sinan Trabulus
SPSalih Pekmezci
Salih Pekmezci
NSNurhan Seyahi
Nurhan Seyahi
Recurrence of glomerulonephritis (GN) is considered an important cause of allograft failure in kidney transplant recipients. It can present after transplantation with complications that are difficult to manage. In this case report, a 53-year-old woman was admitted to the hospital with abdominal pain and swelling in the right lower quadrant during the first month after kidney transplant. Following hospitalization, she complained of sudden-onset dyspnea and chest pain. Thorax computed tomography examination revealed pulmonary embolism (PE); thus, anticoagulation therapy was started. Her 24-h urine proteinuria was quantified as 16695 mg/day, and due to low albumin levels, she was diagnosed with nephrotic syndrome. However, kidney biopsy could not be performed due to the bleeding tendency of the patient. Due to a probable diagnosis of recurrent focal segmental glomerulosclerosis, plasmapheresis was performed. A total of eight plasmapheresis resulted in a complete recovery of the patient considering her proteinuria. In conclusion, recurrence of GN and development of PE due to nephrotic syndrome are well known, but difficult-to-manage. Thus, nephrology follow-up after kidney transplant is crucial. Cite this article as: Korkmaz M, Kaya E, Karakoç A, Trabulus S, Pekmezci S, Seyahi N. A Case of Nephrotic Syndrome Presenting With Pulmonary Embolus in a Kidney Transplant Patient. Turk J Nephrol 2019; 28(3): 236-8.

1 January 2025 in Acta Endocrinologica (Bucharest)
Verified
Journal Article
Closed access
MYM Korkmaz Yilmaz
M Korkmaz Yilmaz
Null cell adenoma (NCA) of the pituitary gland, once considered a distinct subtype of non-functioning pituitary tumors, has been substantially redefined with the advent of transcription factor (TF) immunostaining. The updated WHO classifications emphasize cell lineage differentiation, significantly narrowing the true spectrum of NCAs. To underscore the diagnostic challenges and potential misclassification of NCAs by presenting two illustrative cases and reviewing the evolving diagnostic approach. We describe two diagnostically complex cases initially classified as NCAs due to negative anterior pituitary hormone and TF immunostaining. Both demonstrated atypical clinical features, such as rapid progression and elevated Ki-67 indices, prompting further pathological reassessment. In the first case, follow-up surgeries and additional immunohistochemistry revealed a posterior pituitary tumor—spindle cell oncocytoma. In the second, reevaluation identified hepatocellular carcinoma (HCC) metastasis to the pituitary. These findings highlight the necessity of considering posterior pituitary tumors and metastases in the differential diagnosis of NCAs, especially when clinical or imaging findings suggest alternative etiologies. NCAs must be regarded as a diagnosis of exclusion. Accurate classification depends on thorough clinicopathological correlation, multidisciplinary collaboration, and the use of expanded immunohistochemical panels. Recognition of rare mimickers is crucial for guiding appropriate treatment and improving outcomes.